A patient with TFG::RARA-variant APL, CD56-positive and of poor prognosis, achieved sustained complete remission after VEN plus ATRA, with an overall survival (OS) > 30 months and progression-free survival of 29 months.[20] Youli Li et al.[19] described a 37-year-old woman who relapsed with an RARA-LBD mutation and reinduction with ATRA and arsenic trioxide combined with anthracycline failed. Here, NCAM1 is linked to acute promyelocytic leukemia.